Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,499,960
  • Shares Outstanding, K 2,257,510
  • Annual Sales, $ 26,145 M
  • Annual Income, $ 3,439 M
  • 60-Month Beta 0.74
  • Price/Sales 4.91
  • Price/Cash Flow 12.96
  • Price/Book 2.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.37
  • Number of Estimates 4
  • High Estimate 1.54
  • Low Estimate 1.10
  • Prior Year 1.10
  • Growth Rate Est. (year over year) +24.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.76 +28.74%
on 03/23/20
59.58 -1.12%
on 04/09/20
+1.25 (+2.17%)
since 03/09/20
3-Month
45.76 +28.74%
on 03/23/20
68.34 -13.80%
on 01/22/20
-6.54 (-9.99%)
since 01/09/20
52-Week
42.48 +38.68%
on 07/23/19
68.34 -13.80%
on 01/22/20
+12.93 (+28.12%)
since 04/09/19

Most Recent Stories

More News
Bristol-Myers (BMY) Upgraded to Buy: Here's Why

Bristol-Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BMY : 58.91 (+1.13%)
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer

Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.

PFE : 35.39 (+2.28%)
LLY : 145.73 (-0.34%)
BMY : 58.91 (+1.13%)
ABBV : 79.75 (+1.51%)
Bristol Myers' Applications for Opdivo-Yervoy Combo Accepted

Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.

AZN : 44.66 (+1.85%)
RHHBY : 39.7500 (-1.49%)
MRK : 82.49 (+1.07%)
BMY : 58.91 (+1.13%)
Want To Retire Early? Learn the Intelligent Investing Secret - April 09, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments,...

AMGN : 218.21 (-0.45%)
BMY : 58.91 (+1.13%)
ABBV : 79.75 (+1.51%)
NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate NT-I7 (Hyleukin-7(TM)) in Combination with Nivolumab

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate...

BMY : 58.91 (+1.13%)
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer

--Submissions based on results from Phase 3 CheckMate -9LA trial

BMY : 58.91 (+1.13%)
Signs That Your Trading Will Ruin Your Retirement - April 07, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

BMY : 58.91 (+1.13%)
FBMS : 22.22 (+13.08%)
HCKT : 14.78 (+7.57%)
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $56.80, moving -1.85% from the previous trading session.

BMY : 58.91 (+1.13%)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - April 07, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income...

BBY : 65.99 (+2.39%)
CAH : 50.43 (+2.09%)
BMY : 58.91 (+1.13%)
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.

Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19...

BMY : 58.91 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 60.16
1st Resistance Point 59.54
Last Price 58.91
1st Support Level 58.33
2nd Support Level 57.74

See More

52-Week High 68.34
Last Price 58.91
Fibonacci 61.8% 58.46
Fibonacci 50% 55.41
Fibonacci 38.2% 52.36
52-Week Low 42.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar